A global community and medical education platform for ID clinicians. Useful content curated by an editorial board of published ID experts, independently owned.
I put together a table with therapeutic options for #COVID19 available in the U.S. Happy to read your comments. I have to say, it is really challenging with so many evidence coming our way.
Amid all the #COVIDー19 attention, let's not forget about our other infections with significant unmet medical need, like invasive candidiasis!
Poor C. auris!
#IDtwitter#AntimicrobialResistance
Excellent discussion...
As for the question? We’re increasingly rowing in the same direction, but there’s a long way to go and we might need to think differently about how to get there!
#WorldAMRCongress#StopSuperbugs
SIDP President @jpogue1 and @IDSAInfo President Tom File discuss hospital purchasing & antibiotic use with SIDP member @idpharmd at #WorldAMRCongress. Dr. Pogue starts with discussion of susceptibility breakpoints. We must re-evaluate older abx so new agents are fairly compared.
Neil Clancy from @PittTweet: "..to achieve diagnostic stewardship and demonstrate value we need to start small, share success stories and educate clinicians so the they can do it themselves.." How are you reaching clinicians? #WorldAMRCongress#IDtwitter#AntimicrobialResistance
Great insight from Melissa Stundick @Spero_Tx: "..post-approval costs are estimated @ $400M including sales, marketing, and medical affairs.. 7 years before a company can expect to break even.." Time to think about new ways to connect companies and clinicians? #WorldAMRCongress